

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司 *
KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT

**SHARE PURCHASE BY CHAIRMAN OF THE BOARD, EXECUTIVE
DIRECTOR AND CHIEF EXECUTIVE OFFICER**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to update its shareholders and potential investors on the latest information related to the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that Dr. Youzhi Tong (“**Dr. TONG**”, chairman of the Board, executive director and chief executive officer) has purchased 500,000 shares of the Company at HK\$773,750 (average transaction price was HK\$1.5475 per share) with his own funds through the open market on 19 December 2023 (the “**Share Purchase**”). The Company still satisfies the requirement of maintaining a sufficient public float after Share Purchase.

The Board is of the view that Dr. TONG’s Share Purchase demonstrates his confidence in the overall prospects of the Company, especially in the development prospects of the main products including KX-826 and GT20029 for the treatment of androgenetic alopecia (the “**AGA**”) and acne. Furthermore, the Share Purchase is a full recognition of the long-term investment value in the Company. The Group will further conduct multiple clinical trials to explore the possibility of the commercialization of KX-826 and GT20029.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that KX-826 and GT20029 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, 20 December 2023

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong, Dr. Qun Lu and Dr. Xiang Ni; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

** For identification purpose only*